Anton Kamnev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anton Kamnev has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Anna-Katharina Mautner
Department of Dermatology, Medical University of Vienna, Vienna, Austria
3 shared publicationsJörg Menche
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Max Perutz Labs, University of Vienna, Vienna, Austria
3 shared publicationsKaan Boztug
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD), Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
3 shared publications- Loïc Dupré
Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), INSERM, CNRS, Toulouse III Paul Sabatier University, Toulouse, France
3 shared publications Beatriz Chaves
Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), INSERM, CNRS, Toulouse III Paul Sabatier University, Toulouse, France; National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil; Computational Modeling Group, Oswaldo Cruz Foundation (Fiocruz), Eusébio, Brazil
2 shared publicationsClaire Lacouture
Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), INSERM, CNRS, Toulouse III Paul Sabatier University, Toulouse, France
2 shared publications
Latest Publications
- Open Access
- 28 February 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (3) , 113853
Coordinated ARP2/3 and glycolytic activities regulate the morphological and functional fitness of human CD8+ T cells
- 28 February 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (3) , 113853
Open AccessCoordinated ARP2/3 and glycolytic activities regulate the morphological and functional fitness of human CD8+ T cells
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Coordinated ARP2/3 and Glycolytic Activities Regulate the Morphological Fitness of Human Effector T Cells
T cells rely on actin cytoskeleton remodeling to migrate and assemble the immunological synapse (IS). Here, we investigated how human CD8+ cells regulate their actin cytoskeleton and associated morphological responses according to their metabolic status. The actin-rich lamellipodium sustaining motility and IS was mostly dependent on the ARP2/3 subunit ARPC1B and its regulators WASP and HEM1 as revealed by a morphological screen of T cells from patients with actinopathies. ARP2/3 subunits, actin isoforms and glycolytic enzymes were co-stimulated at the transcriptional level upon IL-2 stimulation. This molecular program scaled with F-actin content and cell spreading in healthy donor T cells and was associated with phenotypic correction of WASP and HEM1 deficient T cells. Blockade of glycolysis but not OXPHOS reduced F-actin density at the lamellipodium and impaired chemokine-driven motility and synaptic adhesion. Thus ARP2/3-mediated lamellipodium assembly scales with glycolysis to adjust morphological responses in effector CD8+ T cells.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessCoordinated ARP2/3 and Glycolytic Activities Regulate the Morphological Fitness of Human Effector T Cells
T cells rely on actin cytoskeleton remodeling to migrate and assemble the immunological synapse (IS). Here, we investigated how human CD8+ cells regulate their actin cytoskeleton and associated morphological responses according to their metabolic status. The actin-rich lamellipodium sustaining motility and IS was mostly dependent on the ARP2/3 subunit ARPC1B and its regulators WASP and HEM1 as revealed by a morphological screen of T cells from patients with actinopathies. ARP2/3 subunits, actin isoforms and glycolytic enzymes were co-stimulated at the transcriptional level upon IL-2 stimulation. This molecular program scaled with F-actin content and cell spreading in healthy donor T cells and was associated with phenotypic correction of WASP and HEM1 deficient T cells. Blockade of glycolysis but not OXPHOS reduced F-actin density at the lamellipodium and impaired chemokine-driven motility and synaptic adhesion. Thus ARP2/3-mediated lamellipodium assembly scales with glycolysis to adjust morphological responses in effector CD8+ T cells.
- Open Access
- 1 July 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (1) , 109318
Morphological profiling of human T and NK lymphocytes by high-content cell imaging
- 1 July 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (1) , 109318
Open AccessMorphological profiling of human T and NK lymphocytes by high-content cell imaging
- Open Access
- 1 January 2018
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 131 (1) , jcs205625
Steric hindrance in the upper 50 kDa domain of the motor Myo2p leads to cytokinesis defects in fission yeast
Cytokinesis in many eukaryotes requires a contractile actomyosin ring that is placed at the division site. In fission yeast, which is an attractive organism for the study of cytokinesis, actomyosin ring assembly and contraction requires the myosin II heavy chain Myo2p. Although myo2-E1, a temperature-sensitive mutant defective in the upper 50 kDa domain of Myo2p, has been studied extensively, the molecular basis of the cytokinesis defect is not understood. Here, we isolate myo2-E1-Sup2, an intragenic suppressor that contains the original mutation in myo2-E1 (G345R) and a second mutation in the upper 50 kDa domain (Y297C). Unlike myo2-E1-Sup1, a previously characterized myo2-E1 suppressor, myo2-E1-Sup2 reverses actomyosin ring contraction defects in vitro and in vivo. Structural analysis of available myosin motor domain conformations suggests that a steric clash in myo2-E1, which is caused by the replacement of a glycine with a bulky arginine, is relieved in myo2-E1-Sup2 by mutation of a tyrosine to a smaller cysteine. Our work provides insight into the function of the upper 50 kDa domain of Myo2p, informs a molecular basis for the cytokinesis defect in myo2-E1, and may be relevant to the understanding of certain cardiomyopathies.
- 1 January 2018
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 131 (1) , jcs205625
Open AccessSteric hindrance in the upper 50 kDa domain of the motor Myo2p leads to cytokinesis defects in fission yeast
Cytokinesis in many eukaryotes requires a contractile actomyosin ring that is placed at the division site. In fission yeast, which is an attractive organism for the study of cytokinesis, actomyosin ring assembly and contraction requires the myosin II heavy chain Myo2p. Although myo2-E1, a temperature-sensitive mutant defective in the upper 50 kDa domain of Myo2p, has been studied extensively, the molecular basis of the cytokinesis defect is not understood. Here, we isolate myo2-E1-Sup2, an intragenic suppressor that contains the original mutation in myo2-E1 (G345R) and a second mutation in the upper 50 kDa domain (Y297C). Unlike myo2-E1-Sup1, a previously characterized myo2-E1 suppressor, myo2-E1-Sup2 reverses actomyosin ring contraction defects in vitro and in vivo. Structural analysis of available myosin motor domain conformations suggests that a steric clash in myo2-E1, which is caused by the replacement of a glycine with a bulky arginine, is relieved in myo2-E1-Sup2 by mutation of a tyrosine to a smaller cysteine. Our work provides insight into the function of the upper 50 kDa domain of Myo2p, informs a molecular basis for the cytokinesis defect in myo2-E1, and may be relevant to the understanding of certain cardiomyopathies.